Mingjun Li

Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial

Dan Liu, Jun Zhou, Yongsheng Wang et al. · BMC Medicine · 2022 · 73 citations · Full text

Silencing of Ribosomal Protein L34 (RPL34) Inhibits the Proliferation and Invasion of Esophageal Cancer Cells

Huijie Fan, Jing Li, Yongxu Jia et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2017 · 36 citations · Full text

Ribosomal Protein L34, Oncology, Esophageal Cancer +13

Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis

Mingjun Li, Wengang Wang, Li Geng et al. · International Journal of Molecular Medicine · 2015 · 34 citations · Full text

Cytoskeleton, Orthopaedic Surgery, Inflammatory Arthritis +20

CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5p

Mingjun Li, Qianqian Wang, Xiaofei Zhang et al. · Cell Cycle · 2021 · 30 citations · Full text

Rna Pumilio Rna, Cell Regulation, Nsclc Tumor Growth +14

Exosomal miR-126 blocks the development of non-small cell lung cancer through the inhibition of ITGA6

Mingjun Li, Qianqian Wang, Xiaofei Zhang et al. · Cancer Cell International · 2020 · 29 citations · Full text